Curanex Pharmaceuticals Inc Operating Cash Flow
Curanex Pharmaceuticals Inc (CURX) reported Operating Cash Flow of -$2.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Curanex Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.08M.
- Curanex Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$954.56K.
- Curanex Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$857.40K.
- Curanex Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.19M.
- Curanex Pharmaceuticals Inc net cash provided by (used in) operating activities for fiscal 2025 was -$10.48M.
- Curanex Pharmaceuticals Inc net cash provided by (used in) operating activities for fiscal 2024 was -$555.58K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.03M 10-Q · filed 2026-08-14 | -$2.89M derived: sum of 3 quarters · filed 2026-08-14 | -$12.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$954.56K 10-Q · filed 2026-05-14 | -$1.81M derived: sum of 2 quarters · filed 2026-05-14 | -$11.00M derived: sum of 3 quarters · filed 2026-05-14 | -$11.29M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$857.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$10.04M derived: sum of 2 quarters · filed 2026-03-30 | -$10.33M derived: sum of 3 quarters · filed 2026-08-14 | -$10.48M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$9.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$9.48M derived: sum of 2 quarters · filed 2026-08-14 | -$9.63M 10-Q · filed 2025-11-17 | -$9.72M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$290.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$440.03K 10-Q · filed 2026-08-14 | -$535.46K derived: sum of 3 quarters · filed 2026-08-14 | -$665.40K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$149.95K 10-Q · filed 2026-05-14 | -$245.38K derived: sum of 2 quarters · filed 2026-05-14 | -$375.32K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$95.43K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$225.37K derived: sum of 2 quarters · filed 2026-03-30 | -$555.58K 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$129.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$460.15K 10-Q · filed 2025-11-17 | ||
| 2024-06-30 | -$330.20K 10-Q · filed 2025-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |